BACKGROUND: Although recent studies suggest high accuracy of breast magnetic resonance imaging (MRI) in predicting @entity41 extent after @entity262 ( @entity262 ), its use is still controversial. In this study, we aimed to identify predictive factors of MRI accuracy after @entity262 to determine a subgroup of @entity1 in whom the use of MRI provides best additional benefit. MATERIALS AND METHODS: Clinicopathologic and molecular profiles of @entity0 @entity1 were investigated and their relationships with MRI accuracy were analyzed. RESULTS: From January 2006 to February 2008, 195 @entity1 received @entity262 and preoperative MRI. In overall, MRI predicted @entity41 extent with higher accuracy than ultrasonography. @entity5 showed highest correlation between MRI-measured and pathologic @entity5 size (r = 0.781) when compared with other subtypes. Multivariate analysis showed age and @entity1722 expression status as independent factors predicting MRI accuracy. When @entity1 were classified based on their age and @entity1722 status, relatively older @entity1 (>45) with @entity1722 -negative @entity5 showed highest MRI accuracy. This finding was further validated using an independent cohort of 63 consecutive @entity1 . CONCLUSION: Age and @entity1722 status independently affected MRI accuracy after @entity262 . This observation may guide more tailored approach in using MRI in @entity0 @entity1 undergoing @entity262 .

Age and @entity1722 expression status affect MRI accuracy in predicting @entity41 extent after XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity41 :: ('MESH:D018365', 'Disease') :: ['residual tumor'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors', 'Triple-negative (TN) tumors'] @entity262 :: ('MESH:D034721', 'Disease') :: ['neo-adjuvant systemic treatment', 'NST'] @entity1722 :: ('2064', 'Gene') :: ['HER2']
@entity262 :: (MESH:D034721,Disease) :: ['neo-adjuvant systemic treatment']
